Tempest Therapeutics (TPST) Share-based Compensation (2011 - 2026)

Tempest Therapeutics has disclosed Share-based Compensation across 16 years of filings, most recently posting -$119000.0 for Q2 2026.

• In Q2 2026, Share-based Compensation fell 110.9% year-over-year to -$119000.0; the TTM figure through Jun 2026 stood at -$708000.0 (down 113.76% YoY), while the FY2025 annual figure was $800000.0, down 84.91% from the prior year.
• Share-based Compensation came in at -$119000.0 for Q2 2026 at Tempest Therapeutics, up from -$1.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $9.5 million in Q4 2022 to a low of -$1.7 million in Q4 2025.
• Average Share-based Compensation over 5 years is $1.1 million, with a median of $563000.0 recorded in 2023.
• Year-over-year, Share-based Compensation surged 3326.98% in 2022 and sank 230.88% in 2025.
• Over 5 years, Share-based Compensation stood at $9.5 million in 2022, then sank by 88.49% to $1.1 million in 2023, then climbed by 21.33% to $1.3 million in 2024, then slumped by 230.88% to -$1.7 million in 2025, then surged by 93.17% to -$119000.0 in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were -$119000.0 in Q2 2026, -$1.7 million in Q4 2025, and $61000.0 in Q3 2025.